CytRx Corporation to Present at OneMed NYC Oncology Investor Conference 2018

LOS ANGELES, May 7, 2018 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Mr. Eric Curtis, President and Chief Operating Officer, will present at the OneMed NYC Oncology Investor Conference 2018 taking place Tuesday, May 8, 2018 at 2:30 P.M. Eastern Time at the law offices of Wilson Sonsini Goodrich & Rosati, in New York.

Mr. Curtis will discuss the LADR™ platform, its broad potential in treating various tumor types, its advantages over antibody drug conjugates and an example of a LADR™ surrogate product proof of concept (aldoxorubicin). He will also address the goal of achieving non-dilutive financing through pharmaceutical partnerships to develop the LADR™ pipeline candidates that are eligible for Investigational New Drug (IND)-enabling studies. Additionally, Mr. Curtis will discuss ongoing clinical studies of aldoxorubicin conducted by NantCell, who owns the worldwide license and IND for the product.

A copy of Mr. Curtis’ presentation can be accessed after 3:30 P.M. Eastern Time / 12:30 P.M. Pacific Time on Tuesday, May 8, 2018 at http://www.cytrx.com/events_calendar.

About OneMed NYC Oncology Investor Conference

The NYC Oncology Investor Conference 2018 hosted by OneMed Forum, and sponsored by the National Foundation for Cancer Research, the International Cancer Impact Fund, Klosters Innovation Partners, Wilson Sonsini Law Firm, Torreya Partners, and Marcum, is the leading conference for early-stage private and public cancer investing. Life science and oncology venture capitalists, family offices, lawyers, pharma executives, startup public and private cancer companies and cancer foundations will join for a discussion of trends, opportunities, and risks in oncology investing, corporate presentations by a select group of public and private oncology companies and updates on cutting edge science.

About CytRx Corporation

CytRx Corporation (NASDAQ: CYTR) is a biopharmaceutical Company specializing in research and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of drug at the tumor. CytRx is rapidly expanding its pipeline of ultra-high potency oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR™ (Linker Activated Drug Release) technology platform, a discovery engine designed to leverage CytRx’s expertise in albumin biology and linker technology for the development of a new class of potential breakthrough anti-cancer therapies. Aldoxorubicin, CytRx’s most advanced drug conjugate, is an improved version of the widely used anti-cancer drug doxorubicin and has been out-licensed to NantCell, Inc.

Forward-Looking Statements

This press release contains forward-looking statements. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks and uncertainties relating to the ability of NantCell, Inc., to obtain regulatory approval for its products that use aldoxorubicin; the ability of NantCell, Inc., to manufacture and commercialize products or therapies that use aldoxorubicin; the amount, if any, of future milestone and royalty payments that we may receive from NantCell, Inc.; our ability to develop new ultra-high potency drug candidates based on our LADR™ technology platform; and other risks and uncertainties described in the most recent annual and quarterly reports filed by CytRx with the Securities and Exchange Commission and current reports filed since the date of CytRx’s most recent annual report. All forward-looking statements are based upon information available to CytRx on the date the statements are first published. CytRx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:
Argot Partners
Michelle Carroll
(212) 600-1902
michelle@argotpartners.com